touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy), to discuss the phase 3 ADAPT study results investigating efgartigimod for the treatment of myasthenia gravis.
The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Questions:
- Could you tell us a little about efgartigimod and its mechanism of action? (0:19)
- Could you give us a brief overview of the ADAPT study objectives and its findings? (2:04)
- What are the potential side effects of efgartigimod? (3:50)
- What role is efgartigimod likely to play in the treatment paradigm of myasthenia gravis, and what further study is needed? (4:46)
Disclosures: Renato Mantegazza has received funding for Travel or Meeting attendance from, Alexion, Argenx, Biomarin Novartis, Catalyst, Merck Serono, UCB, and for Advisory Board participation from Alexion, Argenx, UCB, Regeneron.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
